Affordable Access

Access to the full text

Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice

Authors
  • Alfieri, Carlo1, 2
  • Ruzhytska, Oksana3
  • Vettoretti, Simone1
  • Caldiroli, Lara1
  • Cozzolino, Mario2, 4
  • Messa, Piergiorgio1, 2
  • 1 Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
  • 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
  • 3 Department of Internal Medicine n3, Ternopil State Medical University, 46002 Ternopil, Ukraine
  • 4 Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20122 Milan, Italy
Type
Published Article
Journal
Nutrients
Publisher
MDPI AG
Publication Date
Aug 15, 2019
Volume
11
Issue
8
Identifiers
DOI: 10.3390/nu11081918
PMID: 31443249
PMCID: PMC6723756
Source
PubMed Central
Keywords
License
Green

Abstract

Native hypovitaminosis D (n-hVITD) is frequently found from the early stages of chronic kidney disease (CKD) and its prevalence increases with CKD progression. Even if the implications of n-hVITD in chronic kidney disease-mineral bone disorder (CKD-MBD) have been extensively characterized in the literature, there is a lot of debate nowadays about the so called “unconventional effects” of native vitamin D (25(OH)VitD) supplementation in CKD patients. In this review, highlights of the dimension of the problem of n-hVITD in CKD stages 2–5 ND patients will be presented. In addition, it will focus on the “unconventional effects” of 25(OH)VitD supplementation, the clinical impact of n-hVITD and the most significant interventional studies regarding 25(OH)VitD supplementation in CKD stages 2–5 ND.

Report this publication

Statistics

Seen <100 times